Ludwig Enterprises mRNA Bladder Cancer Study to be Launched
Ludwig Enterprises, Inc. has received Continuing Review Approval from Advarra IRB for its planned clinical study, LL301, focused on evaluating pre- and post-diagnosis and treatment response of patients with Urothelial Carcinoma of the Bladder. The study also includes potential breakthrough genetic results in BCG treatment of bladder cancer, covered in a filed international patent application. CEO Marvin S. Hausman MD expressed excitement for the study's launch and the creation of a personalized patient genetic index to evaluate patient response to BCG immunotherapy.
01/31/2024 - 08:30 AM
SPARKS, NV / ACCESSWIRE / January 31, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased to announce that the company has received Continuing Review Approval on its planned clinical study from Advarra IRB, Columbia, MD. Ludwig clinical study LL301 is titled: "Using Measurements of mRNA and Elisa- based Cytokine/Protein Indices to Evaluate Pre- and Post-Diagnosis and Treatment Response of Patients with Urothelial Carcinoma of the Bladder" .
Marvin S. Hausman MD, CEO, stated: "We have looked forward to the launch of this study and are also pleased to announce that this research and potential breakthrough genetic results in BCG treatment of bladder cancer are covered in a filed international patent application. A personalized patient genetic index will be created to show the presence of bladder cancer as well as evaluate patient response to BCG immunotherapy."
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc., a biotech and healthcare holding company, is a global leader in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor and create solutions to prevent chronic inflammation, the causative agent of illnesses which are responsible for more than 50% of deaths worldwide. Exousia AI, a wholly owned subsidiary has created an Exosomal Targeted Delivery Platform. This transformational technology will lead to the development of new therapeutics and improve the efficacy of existing treatments.
For more information please visit: http://www.ludwigent.com .
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Ludwig Enterprises, Inc.CEO@LUDG.US www.ludwigent.com
SOURCE: Ludwig Enterprises, Inc.
press release on accesswire.com
What is the title of Ludwig's clinical study?
Ludwig's clinical study is titled 'Using Measurements of mRNA and Elisa-based Cytokine/Protein Indices to Evaluate Pre- and Post-Diagnosis and Treatment Response of Patients with Urothelial Carcinoma of the Bladder'.
What is the significance of the Continuing Review Approval received by Ludwig?
The Continuing Review Approval from Advarra IRB allows Ludwig to proceed with its planned clinical study, LL301, focused on evaluating patient response to BCG immunotherapy for bladder cancer.
Who is the CEO of Ludwig Enterprises, Inc.?
Marvin S. Hausman MD is the CEO of Ludwig Enterprises, Inc.
What is the focus of Ludwig's clinical study LL301?
The focus of Ludwig's clinical study LL301 is to evaluate pre- and post-diagnosis and treatment response of patients with Urothelial Carcinoma of the Bladder.
